Skip to content

Study · Non-randomized trial · n = 17 · 2002

7 results

Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.

Matsuda M, Defronzo RA, Glass L, Consoli A, Giordano M, Bressler P, Delprato S

Metabolism: clinical and experimental1 Sept 2002Cited by 64 (Europe PMC)

PMID12200754 (opens in a new tab)DOI10.1053/meta.2002.34700 (opens in a new tab)PepBankPUB-12200754
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialMechanism

    During glucagon infusion, the initial rate of endogenous glucose production rise was lower in T2DM patients than controls.

    In plain wordsDuring glucagon infusion, liver glucose production initially rose more slowly in patients with type 2 diabetes than controls.

    Peptide
    Glucagon
    Outcome
    DecreaseInitial rate of endogenous glucose production rise
    Study

    n = 17

    Comparator
    nondiabetic controls
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.5, 2, 6, and 8 ng. kg(-1). min(-1) · infusion · 4 hoursAs given in this study (human).

    Source sentences

    Summary
    During the first 2 hours (0 to 120 minutes) of glucagon infusion, EGP increased sharply in both groups, and the initial rate of rise in EGP was higher in control versus diabetic subjects.
    2 context sentences
    Summary · context
    Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects
    Summary · context
    Each glucagon infusion study was performed on a separate day and in random order.
  2. 02HumanNon-randomized trialMechanism

    During the last 2 hours of glucagon infusion, endogenous glucose production tended to be higher in T2DM patients than controls at the 3 lower rates.

    In plain wordsDuring later glucagon infusion, liver glucose production tended to be higher in patients with type 2 diabetes than controls at lower rates.

    Peptide
    Glucagon
    Outcome
    IncreaseLate endogenous glucose production at lower rates
    Study

    n = 17

    Comparator
    nondiabetic controls
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.5, and 2 ng. kg(-1). min(-1) · infusion · 4 hoursAs given in this study (human).

    Source sentences

    Summary
    During the last 2 hours (120 to 240 minutes) of glucagon infusion, EGP in the diabetics tended to be higher than controls during the 3 lower glucagon infusion rates and this difference reached statistical significance (P <.05 to.01) during the 6 and 8 ng. kg(-1). min(-1) infusions.
    2 context sentences
    Summary · context
    Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects
    Summary · context
    Each glucagon infusion study was performed on a separate day and in random order.
  3. 03HumanNon-randomized trialMechanism

    During late glucagon infusion at 6 ng. kg(-1). min(-1), endogenous glucose production was higher in T2DM patients than controls (P <.05 to.01).

    In plain wordsAt the higher glucagon infusion rate, later liver glucose production was greater in patients with type 2 diabetes than controls.

    Peptide
    Glucagon
    Outcome
    IncreaseLate endogenous glucose production at 6 ng rate
    Study

    n = 17

    Comparator
    nondiabetic controls
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    6 ng. kg(-1). min(-1) · infusion · 4 hoursAs given in this study (human).

    Source sentences

    Summary
    During the last 2 hours (120 to 240 minutes) of glucagon infusion, EGP in the diabetics tended to be higher than controls during the 3 lower glucagon infusion rates and this difference reached statistical significance (P <.05 to.01) during the 6 and 8 ng. kg(-1). min(-1) infusions.
    2 context sentences
    Summary · context
    Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects
    Summary · context
    Each glucagon infusion study was performed on a separate day and in random order.
  4. 04HumanNon-randomized trialMechanism

    During late glucagon infusion at 8 ng. kg(-1). min(-1), endogenous glucose production was higher in T2DM patients than controls (P <.05 to.01).

    In plain wordsAt the higher glucagon infusion rate, later liver glucose production was greater in patients with type 2 diabetes than controls.

    Peptide
    Glucagon
    Outcome
    IncreaseLate endogenous glucose production at 8 ng rate
    Study

    n = 17

    Comparator
    nondiabetic controls
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    8 ng. kg(-1). min(-1) · infusion · 4 hoursAs given in this study (human).

    Source sentences

    Summary
    During the last 2 hours (120 to 240 minutes) of glucagon infusion, EGP in the diabetics tended to be higher than controls during the 3 lower glucagon infusion rates and this difference reached statistical significance (P <.05 to.01) during the 6 and 8 ng. kg(-1). min(-1) infusions.
    2 context sentences
    Summary · context
    Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects
    Summary · context
    Each glucagon infusion study was performed on a separate day and in random order.
  5. 05HumanNon-randomized trialMechanism

    During 240-360 minutes, glucose disappearance stimulation was impaired in T2DM patients versus controls after all 5 glucagon infusion rates (P <.05).

    In plain wordsAfter glucagon infusion, glucose removal from blood was impaired in patients with type 2 diabetes compared with controls at all tested rates.

    Peptide
    Glucagon
    Outcome
    DecreasePost-infusion glucose disappearance
    Study

    n = 17

    Comparator
    nondiabetic controls
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.5, 2, 6, and 8 ng. kg(-1). min(-1) · infusion · 4 hoursAs given in this study (human).

    Source sentences

    Summary
    During the 2 hours following cessation of glucagon (240- to 360-minute time period), the stimulation of glucose disappearance from plasma was impaired (P <.05) during all 5 glucagon infusion rates in the diabetics compared to controls.
    2 context sentences
    Summary · context
    Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects
    Summary · context
    Each glucagon infusion study was performed on a separate day and in random order.
  6. 06HumanNon-randomized trialMechanism

    In nondiabetic controls, endogenous glucose production increased sharply during the first 2 hours of glucagon infusion.

    In plain wordsIn participants without diabetes, liver glucose production increased sharply during the first two hours of glucagon infusion.

    Peptide
    Glucagon
    Outcome
    IncreaseEarly endogenous glucose production in controls
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.5, 2, 6, and 8 ng. kg(-1). min(-1) · infusion · 4 hoursAs given in this study (human).

    Source sentences

    Summary
    During the first 2 hours (0 to 120 minutes) of glucagon infusion, EGP increased sharply in both groups, and the initial rate of rise in EGP was higher in control versus diabetic subjects.
    2 context sentences
    Summary · context
    Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects
    Summary · context
    Each glucagon infusion study was performed on a separate day and in random order.
  7. 07HumanNon-randomized trialMechanism

    In T2DM patients, endogenous glucose production increased sharply during the first 2 hours of glucagon infusion.

    In plain wordsIn patients with type 2 diabetes, liver glucose production increased sharply during the first two hours of glucagon infusion.

    Peptide
    Glucagon
    Outcome
    IncreaseEarly endogenous glucose production in T2DM
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.2, 0.5, 2, 6, and 8 ng. kg(-1). min(-1) · infusion · 4 hoursAs given in this study (human).

    Source sentences

    Summary
    During the first 2 hours (0 to 120 minutes) of glucagon infusion, EGP increased sharply in both groups, and the initial rate of rise in EGP was higher in control versus diabetic subjects.
    2 context sentences
    Summary · context
    Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects
    Summary · context
    Each glucagon infusion study was performed on a separate day and in random order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.